PMID- 23884642
OWN - NLM
STAT- MEDLINE
DCOM- 20130917
LR  - 20211021
IS  - 2157-6564 (Print)
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 2
IP  - 9
DP  - 2013 Sep
TI  - Cord blood transplantation for cure of HIV infections.
PG  - 635-7
LID - 10.5966/sctm.2012-0089 [doi]
AB  - HIV infection has not been cured by antiretroviral drugs or gene therapy, but it 
      has been cured by a hematopoietic cell transplantation (HCT) that was performed 
      for a patient with acute myeloid leukemia and HIV infection using peripheral 
      blood stem cells from an adult donor homozygous for CCR5-Delta32 (CCR5-Delta32/Delta32). HIV 
      has remained undetectable more than 6 years after discontinuation of 
      antiretroviral therapy. However, this approach cannot be readily generalized 
      because of the low prevalence of the CCR5-Delta32 allele and the need for a very 
      close human leukocyte antigen (HLA) match between adult donors and recipients, as 
      when bone marrow or peripheral blood stem cell transplants are performed. In 
      contrast, cord blood (CB) transplants require less stringent HLA matching. CB 
      units are being screened to develop an inventory of cryopreserved homozygous 
      CCR5-Delta32 units available for HCT. One hundred eighty homozygous CCR5-Delta32 units 
      have been identified, and 300 units are projected to provide for white pediatric 
      patients a 73.6% probability of finding an adequately HLA-matched unit with a 
      minimal cell dose of >/=2.5 x 10(7) total nucleated cells (TNC) per kilogram and 
      for white adults a 27.9% probability. With a minimal cell dose requirement of >/=1 
      x 10(7) TNC per kilogram, the corresponding projected probabilities are 85.6% and 
      82.1%. CB transplantation does not require as stringent an HLA match between 
      donor and recipient as bone marrow or peripheral blood HCTs, and HCT using cord 
      bloods from donors homozygous for CCR5-Delta32 is, at the present time, the only 
      feasible means of treatment of reasonable numbers of patients who are infected 
      with HIV.
FAU - Petz, Lawrence
AU  - Petz L
AD  - StemCyte International Cord Blood Center, Covina, CA, USA. lpeltz@stemcyte.com
LA  - eng
PT  - Journal Article
DEP - 20130724
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, CCR5)
SB  - IM
MH  - Adult
MH  - Bone Marrow Transplantation/adverse effects
MH  - Cell Count
MH  - *Cord Blood Stem Cell Transplantation
MH  - Cryopreservation
MH  - Graft vs Host Disease/etiology/immunology/*prevention & control
MH  - HIV Infections/immunology/*therapy
MH  - HLA Antigens/immunology
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Histocompatibility Testing
MH  - Homozygote
MH  - Humans
MH  - Mutation
MH  - Probability
MH  - Receptors, CCR5/deficiency/*genetics/immunology
MH  - Tissue Donors
PMC - PMC3754463
EDAT- 2013/07/26 06:00
MHDA- 2013/09/18 06:00
PMCR- 2014/09/01
CRDT- 2013/07/26 06:00
PHST- 2013/07/26 06:00 [entrez]
PHST- 2013/07/26 06:00 [pubmed]
PHST- 2013/09/18 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - sctm.2012-0089 [pii]
AID - 3842212 [pii]
AID - 10.5966/sctm.2012-0089 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2013 Sep;2(9):635-7. doi: 10.5966/sctm.2012-0089. Epub 
      2013 Jul 24.